MSAC brands J&J 'unethical'

Posted 8 July 2024 AM

MSAC has branded a pricing proposal by Johnson & Johnson Innovative Medicine as 'unethical' - exposing the depth of bitterness in negotiations which have ended with the company's CAR T therapy for multiple myeloma, Carvykti, finally winning a recommendation.

The long-awaited good news for patients came hand-in-hand with a scathing rebuke from MSAC delivered in the 11-page Public Summary Document, which some are privately terming a "dummy spit" by the Committee, unhappy about the very public campaign which questioned why a recommendation was so slow coming.

To see the whole article, please login